Derazantinib (DZB), an oral fibroblast growth factor receptor inhibitor (FGFRi), shows promising activity in PDX-tumour models with aberrations in FGFR1-3-MedSci.cn

Derazantinib (DZB), an oral fibroblast growth factor receptor inhibitor (FGFRi), shows promising activity in PDX-tumour models with aberrations in FGFR1-3

Mcsheehy, PM

ANNALS OF ONCOLOGY, 2020; 31 (): S473

科室
- - 订阅+
  - 更多科室
工具
服务